Qiang Gao - Sinovac Biotech Vice President Research and Development

Mr. Qiang Gao serves as Vice President Research and Development of the company. Mr. Gao joined Sinovac Beijing in 2002 and has served as quality control manager, quality assurance manager, RD manager and RD director at Sinovac Beijing in the past years, and the general manager of Sinovac RD since 2010. He is responsible for developing our new vaccine products, including EV71 vaccine
Age: 40  President Since 2016      
86-10-5693-1800  http://www.sinovacbio.com
Gao received a master?s degree and a bachelor?s degree in microbiology from the University of Agriculture, PRC.

Management Efficiency

The company has Return on Asset of 6.42 % which means that on every $100 spent on asset it made $6.42 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.53 % implying that it generated $11.53 on every 100 dollars invested.
The company has 20.98M in debt with debt to equity (D/E) ratio of 6.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Sinovac Biotech has Current Ratio of 4.91 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Joyce LeeZoetis
James MichaudPerrigo Company plc
Alok SonigDr Reddys Laboratories Ltd
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
K RaoDr Reddys Laboratories Ltd
Daniel PlewRegeneron Pharmaceuticals
Jay MarkowitzRegeneron Pharmaceuticals
Saumen ChakrabortyDr Reddys Laboratories Ltd
Peter PowchikRegeneron Pharmaceuticals
Louis YuPerrigo Company plc
Heidi ChenZoetis
Samiran DasDr Reddys Laboratories Ltd
Roman TrawickiZoetis
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Michael StewartPerrigo Company plc
George YancopoulosRegeneron Pharmaceuticals
Charles WagnerVertex Pharmaceuticals Incorpor
Michael PariniVertex Pharmaceuticals Incorpor
Stefan WeiskopfZoetis
Glenn DavidZoetis
Douglas BoothePerrigo Company plc

Entity Summary

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the Peoples Republic of China. Sinovac Biotech Ltd. was founded in 1999 and is based in Beijing, the Peoples Republic of China. Sinovac Biotech operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 735 people.Sinovac Biotech Ltd (SVA) is traded on BATS Exchange in USA and employs 735 people.

Sinovac Biotech Leadership Team

Weidong Yin, Chairman, CEO and President Managing Director, Secretary, Chairman of Sinovac Hong Kong, Chairman of Tangshan Yian, Chairman of Sinovac Dalian and Director of Sinovac Biotech Co
Meng Mei, Independent Director
Pengfei Li, Director
Simon Anderson, Independent Director
Shan Fu, Independent Director
Stephanie Carrington, IR Contact Officer
Guowei Wang, Director
Nan Wang, CFO and VP of Bus. Devel.
Fung Hoi, Director
Jing Li, Vice President Quality and Production
Helen Yang, IR Contact Officer
Yuk Lo, Independent Director
Jue Lee, Independent Director
Xiaomei Yin, Vice President Sales and Marketing
Jianzeng Cao, Director
Qiang Gao, Vice President Research and Development
Ming Xia, VP of Sales and Marketing

Stock Performance Indicators

Current Sentiment - SVA

Sinovac Biotech Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Sinovac Biotech Ltd. What is your outlook on investing in Sinovac Biotech Ltd? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased few shares of
a day ago
Traded for 188.14
Purchased a lot of shares of
a day ago
Traded for 150.35
Purchased few shares of
a day ago
Traded for 175.29
Purchased a lot of shares of
a day ago
Traded for 152.77
Purchased over 300 shares of
a day ago
Traded for 9.25
See also World Market Map. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Search macroaxis.com